To assess the impact of lymphoid versus Flt3L-mediated adjuvant effects on protective tumor immunity, we utilized two different tumor models which provide compatibility with the LCMV-GP system due to the expression of a gp33 minigene [38,39]. Here, FLT3LG is linked to neoplasm.